secwatch.observer — SEC 8-K summary
======================================

Issuer:     Gossamer Bio, Inc. (GOSS)
CIK:        0001728117
Form:       8-K
Filed at:   2022-12-06T23:59:59+00:00
Accession:  0001728117-22-000102
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gossamer Bio's Phase 2 TORREY study meets primary endpoint; seralutinib reduces PVR in PAH
--------------------------------------------------------------------------------

- Phase 2 TORREY met primary endpoint: placebo-corrected PVR reduction of 96.1 dynes (14.3%, p=0.031).
- Secondary endpoint 6MWD numerically favored seralutinib by 6.5 meters (not statistically significant).
- In FC III patients: 21% PVR reduction (p=0.043) and 37m 6MWD improvement (p=0.048) vs placebo.
- NT-proBNP reduced by 408.3 ng/L at Week 24 (p=0.0012); right heart structure/function improved.
- Seralutinib well tolerated; cough most common TEAE (43% vs 38% placebo), no subdural hematomas.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728117/000172811722000102/0001728117-22-000102-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728117/000172811722000102/goss-20221206.htm
  HTML page:      https://secwatch.observer/filing/0001728117-22-000102

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer